The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsMatthew Kennedy, Mark S. Forman, John Palcza et al.|Science Translational Medicine|2016Cited by 416
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s DiseaseJack D. Scott, Andrew W. Stamford, Sarah W. Li et al.|Journal of Medicinal Chemistry|2016Cited by 165
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ ReductionAndrew W. Stamford, William J. Greenlee, Jack D. Scott et al.|ACS Medicinal Chemistry Letters|2012Cited by 99
Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in miceShenhai Gong, Xia Chen|Journal of Translational Medicine|2021Cited by 88
Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-AnalysisTaobi Huang, Yuping Wang, Xia Chen et al.|Frontiers in Oncology|2021Cited by 45